{"id":"b-ftc-taf","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bictegravir (B) is an integrase strand transfer inhibitor that blocks HIV integration into host DNA. Emtricitabine (FTC) and tenofovir alafenamide (TAF) are nucleoside/nucleotide reverse transcriptase inhibitors that prevent reverse transcription of viral RNA. Together, these three agents target multiple steps of the HIV replication cycle.","oneSentence":"B/FTC/TAF is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:24.046Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"}]},"trialDetails":[{"nctId":"NCT02881320","phase":"PHASE2, PHASE3","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-09-21","conditions":"HIV-1 Infection","enrollment":177},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT07476339","phase":"PHASE4","title":"REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks","status":"NOT_YET_RECRUITING","sponsor":"CAN Community Health","startDate":"2026-03-23","conditions":"HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV","enrollment":200},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT07055451","phase":"PHASE1","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-08-12","conditions":"HIV-1-infection","enrollment":16},{"nctId":"NCT06104306","phase":"PHASE4","title":"Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"HIV-1-infection","enrollment":33},{"nctId":"NCT05052996","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-05","conditions":"HIV-1 Infection","enrollment":142},{"nctId":"NCT01854775","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05-06","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":129},{"nctId":"NCT03696160","phase":"PHASE3","title":"The Late Presenter Treatment Optimisation Study","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2019-03-05","conditions":"HIV/AIDS","enrollment":447},{"nctId":"NCT06766331","phase":"NA","title":"Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2028-04-03","conditions":"Opioid Use Disorder, HIV, Hepatitis C Virus","enrollment":60},{"nctId":"NCT06613685","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-21","conditions":"HIV-1-infection","enrollment":675},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT06630286","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-09","conditions":"HIV-1-infection","enrollment":609},{"nctId":"NCT06333808","phase":"PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-03-25","conditions":"HIV-1-infection","enrollment":577},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT05585307","phase":"PHASE1","title":"Study of Novel Antiretrovirals in Participants With HIV-1","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-10-26","conditions":"HIV-1-infection","enrollment":49},{"nctId":"NCT06374758","phase":"PHASE4","title":"Accelerated ART Initiation for PWHIV Who Are Out of Care","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2024-04-29","conditions":"HIV Infections, ART, Noncompliance, Patient","enrollment":120},{"nctId":"NCT03547908","phase":"PHASE3","title":"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-05-30","conditions":"HIV-1/HBV Co-Infection","enrollment":244},{"nctId":"NCT06830668","phase":"PHASE4","title":"Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation","status":"NOT_YET_RECRUITING","sponsor":"National Center for AIDS/STD Control and Prevention, China CDC","startDate":"2025-02-28","conditions":"HIV Infection, HIV","enrollment":250},{"nctId":"NCT02578550","phase":"PHASE1","title":"A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-11","conditions":"Healthy","enrollment":126},{"nctId":"NCT04661397","phase":"PHASE1","title":"A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-01-05","conditions":"Healthy","enrollment":37},{"nctId":"NCT02984852","phase":"PHASE1","title":"Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT04066881","phase":"PHASE2","title":"A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2020-12-15","conditions":"HIV Infections","enrollment":1512},{"nctId":"NCT04950530","phase":"PHASE1","title":"The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers","status":"COMPLETED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2022-12-22","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT04585737","phase":"PHASE4","title":"Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF","status":"COMPLETED","sponsor":"Charlotte-Paige Rolle, MD","startDate":"2020-10-05","conditions":"HIV I Infection","enrollment":222},{"nctId":"NCT04143594","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-11-22","conditions":"HIV-1-infection","enrollment":183},{"nctId":"NCT06619288","phase":"","title":"Good-first: B/F/TAF As First-line ART","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-07-01","conditions":"HIV Infection","enrollment":630},{"nctId":"NCT05663892","phase":"PHASE4","title":"Drug-Drug Interaction Study in Trans Women Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maple Leaf Research","startDate":"2022-11-23","conditions":"Hiv, Transgenderism","enrollment":45},{"nctId":"NCT03580668","phase":"","title":"Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-11-13","conditions":"HIV-1-infection","enrollment":201},{"nctId":"NCT03960645","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-06-28","conditions":"HIV-1-infection","enrollment":62},{"nctId":"NCT05243602","phase":"PHASE4","title":"BFTAF Elderly Switch Study","status":"COMPLETED","sponsor":"University of Nairobi","startDate":"2022-02-01","conditions":"HIV-1-infection","enrollment":520},{"nctId":"NCT06375304","phase":"PHASE4","title":"The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-05-01","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT04897243","phase":"","title":"Antiretroviral Speed Access Program","status":"UNKNOWN","sponsor":"Dr. Bertrand Lebouche","startDate":"2019-08-01","conditions":"HIV Infection","enrollment":75},{"nctId":"NCT05122754","phase":"PHASE4","title":"Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2021-12-08","conditions":"HIV-1-infection","enrollment":150},{"nctId":"NCT04249037","phase":"PHASE4","title":"Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2020-12-15","conditions":"HIV/AIDS","enrollment":10},{"nctId":"NCT03797014","phase":"PHASE4","title":"B/F/TAF Switch Study for HIV-HBV Coinfection","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-04-30","conditions":"HIV-1-infection, Hepatitis B","enrollment":28},{"nctId":"NCT03998176","phase":"PHASE4","title":"Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2019-10-09","conditions":"HIV-1-infection","enrollment":43},{"nctId":"NCT03916328","phase":"PHASE4","title":"BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study","status":"UNKNOWN","sponsor":"MU-JHU CARE","startDate":"2019-12-03","conditions":"Bone Loss","enrollment":330},{"nctId":"NCT03656783","phase":"PHASE3","title":"Effects of Biktarvy on CFR in Stable HIV Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-09-14","conditions":"HIV","enrollment":25},{"nctId":"NCT04296695","phase":"PHASE4","title":"Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":250},{"nctId":"NCT03532425","phase":"PHASE4","title":"B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2018-10-29","conditions":"HIV-1-infection","enrollment":28},{"nctId":"NCT03348163","phase":"PHASE4","title":"(mo)BETTA Trial in Transwomen for Optimization of ART","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-06-06","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT03251144","phase":"PHASE1, PHASE2","title":"Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2019-04-01","conditions":"HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction","enrollment":26},{"nctId":"NCT04009057","phase":"","title":"Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-07-09","conditions":"HIV-1-infection","enrollment":143},{"nctId":"NCT03499483","phase":"PHASE4","title":"Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)","status":"COMPLETED","sponsor":"Fenway Community Health","startDate":"2019-01-24","conditions":"HIV Prevention","enrollment":52},{"nctId":"NCT02607956","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":657},{"nctId":"NCT04302896","phase":"EARLY_PHASE1","title":"Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs","status":"COMPLETED","sponsor":"Rhonda Brand","startDate":"2020-08-31","conditions":"Medication Adherence, HIV","enrollment":30},{"nctId":"NCT02607930","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-13","conditions":"HIV-1 Infection","enrollment":631},{"nctId":"NCT04039217","phase":"PHASE4","title":"Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-30","conditions":"ART, HIV","enrollment":20},{"nctId":"NCT03110380","phase":"PHASE3","title":"Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-06-12","conditions":"HIV-1-infection","enrollment":567},{"nctId":"NCT05147740","phase":"PHASE4","title":"Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age","status":"UNKNOWN","sponsor":"Tulika Singh, MD","startDate":"2021-07-01","conditions":"HIV-1-infection","enrollment":50},{"nctId":"NCT03350672","phase":"PHASE4","title":"Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Philadelphia Fight","startDate":"2017-11-16","conditions":"Hiv","enrollment":37},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03739866","phase":"PHASE1","title":"Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-11-26","conditions":"HIV-1 Infection","enrollment":53},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT03405935","phase":"PHASE3","title":"Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-03-01","conditions":"HIV-1 Infection","enrollment":86},{"nctId":"NCT02603120","phase":"PHASE3","title":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02600819","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-14","conditions":"HIV-1 Infection","enrollment":55},{"nctId":"NCT04600687","phase":"NA","title":"B/F/TAF Ease of Swallowability Trial","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2018-11-06","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT04236453","phase":"PHASE1","title":"A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents","status":"TERMINATED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-01-23","conditions":"Healthy","enrollment":16},{"nctId":"NCT02397694","phase":"PHASE2","title":"Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-03-23","conditions":"HIV-1 Infection","enrollment":98},{"nctId":"NCT03115736","phase":"PHASE2","title":"TAF for HIV-HBV With Renal Dysfunction","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-05-23","conditions":"HIV and Hepatitis B Coinfection","enrollment":24},{"nctId":"NCT02652624","phase":"PHASE3","title":"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-02-19","conditions":"HIV-1 Infection","enrollment":472},{"nctId":"NCT04155554","phase":"PHASE3","title":"Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Senese","startDate":"2020-01-29","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT04225325","phase":"PHASE4","title":"Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).","status":"UNKNOWN","sponsor":"ADRIANO LAZZARIN, MD","startDate":"2018-05-07","conditions":"HIV-1-infection","enrollment":112},{"nctId":"NCT03549312","phase":"PHASE4","title":"Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy","status":"UNKNOWN","sponsor":"Saskatchewan Health Authority - Regina Area","startDate":"2018-02-01","conditions":"HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence","enrollment":25},{"nctId":"NCT04132674","phase":"PHASE4","title":"Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed","status":"UNKNOWN","sponsor":"Vancouver Infectious Diseases Centre","startDate":"2018-11-26","conditions":"Human Immunodeficiency Virus I Infection, Drug Use","enrollment":40},{"nctId":"NCT04054089","phase":"PHASE4","title":"Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)","status":"UNKNOWN","sponsor":"Cristina Mussini","startDate":"2019-09","conditions":"HIV Infections","enrollment":66},{"nctId":"NCT02276612","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-03","conditions":"HIV","enrollment":60},{"nctId":"NCT02071082","phase":"PHASE3","title":"Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-02-25","conditions":"HIV, HBV","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"B/FTC/TAF","genericName":"B/FTC/TAF","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"B/FTC/TAF is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}